186 related articles for article (PubMed ID: 25746763)
1. Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor.
Jain CK; Roychoudhury S; Majumder HK
Biochim Biophys Acta; 2015 May; 1853(5):1195-204. PubMed ID: 25746763
[TBL] [Abstract][Full Text] [Related]
2. Identification of decatenation G2 checkpoint impairment independently of DNA damage G2 checkpoint in human lung cancer cell lines.
Nakagawa T; Hayashita Y; Maeno K; Masuda A; Sugito N; Osada H; Yanagisawa K; Ebi H; Shimokata K; Takahashi T
Cancer Res; 2004 Jul; 64(14):4826-32. PubMed ID: 15256452
[TBL] [Abstract][Full Text] [Related]
3. Revised genetic requirements for the decatenation G2 checkpoint: the role of ATM.
Bower JJ; Zhou Y; Zhou T; Simpson DA; Arlander SJ; Paules RS; Cordeiro-Stone M; Kaufmann WK
Cell Cycle; 2010 Apr; 9(8):1617-28. PubMed ID: 20372057
[TBL] [Abstract][Full Text] [Related]
4. Geminin overexpression prevents the completion of topoisomerase IIα chromosome decatenation, leading to aneuploidy in human mammary epithelial cells.
Gardner L; Malik R; Shimizu Y; Mullins N; ElShamy WM
Breast Cancer Res; 2011 May; 13(3):R53. PubMed ID: 21595939
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Tse AN; Schwartz GK
Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
[TBL] [Abstract][Full Text] [Related]
6. Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint.
Kozuki T; Chikamori K; Surleac MD; Micluta MA; Petrescu AJ; Norris EJ; Elson P; Hoeltge GA; Grabowski DR; Porter ACG; Ganapathi RN; Ganapathi MK
Nucleic Acids Res; 2017 Jun; 45(10):5995-6010. PubMed ID: 28472494
[TBL] [Abstract][Full Text] [Related]
7. MCPH1 Lack of Function Enhances Mitotic Cell Sensitivity Caused by Catalytic Inhibitors of Topo II.
Arroyo M; Sánchez A; Cañuelo A; Heredia-Molina RF; Martínez-Molina E; Clarke DJ; Marchal JA
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32276518
[TBL] [Abstract][Full Text] [Related]
8. Mitotic entry upon Topo II catalytic inhibition is controlled by Chk1 and Plk1.
Arroyo M; Cañuelo A; Calahorra J; Hastert FD; Sánchez A; Clarke DJ; Marchal JA
FEBS J; 2020 Nov; 287(22):4933-4951. PubMed ID: 32144855
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.
Bower JJ; Karaca GF; Zhou Y; Simpson DA; Cordeiro-Stone M; Kaufmann WK
Oncogene; 2010 Aug; 29(34):4787-99. PubMed ID: 20562910
[TBL] [Abstract][Full Text] [Related]
10. Rad9A is required for G2 decatenation checkpoint and to prevent endoreduplication in response to topoisomerase II inhibition.
Greer Card DA; Sierant ML; Davey S
J Biol Chem; 2010 May; 285(20):15653-15661. PubMed ID: 20305300
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle checkpoint function in bladder cancer.
Doherty SC; McKeown SR; McKelvey-Martin V; Downes CS; Atala A; Yoo JJ; Simpson DA; Kaufmann WK
J Natl Cancer Inst; 2003 Dec; 95(24):1859-68. PubMed ID: 14679155
[TBL] [Abstract][Full Text] [Related]
12. Daurinol, a catalytic inhibitor of topoisomerase IIα, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase.
Kang K; Nho CW; Kim ND; Song DG; Park YG; Kim M; Pan CH; Shin D; Oh SH; Oh HS
Int J Oncol; 2014 Aug; 45(2):558-66. PubMed ID: 24841075
[TBL] [Abstract][Full Text] [Related]
13. Metnase mediates chromosome decatenation in acute leukemia cells.
Wray J; Williamson EA; Sheema S; Lee SH; Libby E; Willman CL; Nickoloff JA; Hromas R
Blood; 2009 Aug; 114(9):1852-8. PubMed ID: 19458360
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel catalytic inhibitor of topoisomerase II alpha that engages distinct mechanisms in p53
Lee SF; Hirpara JL; Qu J; Yadav SK; Sachaphibulkij K; Pervaiz S
Cancer Lett; 2022 Feb; 526():284-303. PubMed ID: 34843865
[TBL] [Abstract][Full Text] [Related]
15. Chromosomes with two intact axial cores are induced by G2 checkpoint override: evidence that DNA decatenation is not required to template the chromosome structure.
Andreassen PR; Lacroix FB; Margolis RL
J Cell Biol; 1997 Jan; 136(1):29-43. PubMed ID: 9008701
[TBL] [Abstract][Full Text] [Related]
16. Metnase mediates resistance to topoisomerase II inhibitors in breast cancer cells.
Wray J; Williamson EA; Royce M; Shaheen M; Beck BD; Lee SH; Nickoloff JA; Hromas R
PLoS One; 2009; 4(4):e5323. PubMed ID: 19390626
[TBL] [Abstract][Full Text] [Related]
17. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells/.
Downes CS; Clarke DJ; Mullinger AM; Giménez-Abián JF; Creighton AM; Johnson RT
Nature; 1994 Dec; 372(6505):467-70. PubMed ID: 7984241
[TBL] [Abstract][Full Text] [Related]
18. Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.
Islam MS; Park S; Song C; Kadi AA; Kwon Y; Rahman AF
Eur J Med Chem; 2017 Jan; 125():49-67. PubMed ID: 27654394
[TBL] [Abstract][Full Text] [Related]
19. (S)-Erypoegin K, an isoflavone isolated from Erythrina poeppigiana, is a novel inhibitor of topoisomerase IIα: Induction of G2 phase arrest in human gastric cancer cells.
Hikita K; Yamakage Y; Okunaga H; Motoyama Y; Matsuyama H; Matsuoka K; Murata T; Nakayoshi T; Oda A; Kato K; Tanaka H; Asao N; Dan S; Kaneda N
Bioorg Med Chem; 2021 Jan; 30():115904. PubMed ID: 33341500
[TBL] [Abstract][Full Text] [Related]
20. HY-1 induces G(2)/M cell cycle arrest in human colon cancer cells through the ATR-Chk1-Cdc25C and Weel pathways.
Zhao Y; Wu Z; Zhang Y; Zhu L
Cancer Sci; 2013 Aug; 104(8):1062-6. PubMed ID: 23600770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
